Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose escalation and expansion of elironrasib and daraxonrasib in KRAS G12C-mutated solid tumors
2023-508178-27-00Phase 2Authorised
- Sponsor
- Revolution Medicines
- Start
- Jun 2024
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of elironrasib and daraxonrasib in Nonhematologic neoplasms (3 arms), sponsored by Revolution Medicines. Planned start Jun 2024; status: authorised.
02
Drugs
elironrasibdaraxonrasib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-508178-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508178-27-00.